epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Benicar HCT
    olmesartan medoxomil/ hydrochlorothiazide
  • remove Xultophy 100/ 3.6
    insulin degludec/ liraglutide

multicheck MultiCheck Results - 3 Interactions

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face Benicar HCT (olmesartan medoxomil/ hydrochlorothiazide) + Xultophy 100/3.6 (insulin degludec/ liraglutide)

Monitor/Modify Tx


hydrochlorothiazide + insulin

monitor glucose, potassium: combo may incr. risk of hypokalemia; may decr. antidiabetic agent efficacy (additive effects, antagonistic effects)

hydrochlorothiazide + liraglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

olmesartan medoxomil + insulin

monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

Additional Considerations

Smiley face Smiley face liraglutide in Xultophy 100/3.6

caution advised with concurrent oral drugs requiring rapid onset; liraglutide delays gastric emptying

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information